Drugs known as GLP-1 medications, which are widely used for treating type 2 diabetes and helping with weight loss, have become extremely popular in recent years.
Medicines such as semaglutide and tirzepatide are now used by millions of people, and it is estimated that about one in eight adults in the United States has taken them.
These drugs are not only effective for lowering blood sugar and helping people lose weight, but they also provide important benefits for heart health.
However, a new large study has raised concerns about what happens when people stop taking these medications. The research, carried out by scientists at Washington University School of Medicine in St. Louis, found that stopping GLP-1 drugs can increase the risk of heart attack, stroke, and death.
The findings were published in BMJ Medicine and are based on data from more than 333,000 U.S. veterans with type 2 diabetes. The researchers followed these individuals for up to three years to understand how different patterns of medication use affected their health.
GLP-1 drugs work by helping the body control blood sugar, reducing appetite, and supporting weight loss.
They also improve several important risk factors for heart disease, including lowering blood pressure, reducing inflammation, and improving cholesterol levels. Because of these benefits, they are now seen as important tools not only for diabetes care but also for protecting the heart.
In the study, researchers compared people who continuously took GLP-1 medications with those who stopped or interrupted treatment. They also compared these groups with people taking another type of diabetes medication called sulfonylureas.
The results showed a clear pattern. People who stayed on GLP-1 drugs for the full three years had the lowest risk of major cardiovascular problems. These include heart attacks, strokes, and death. Their risk was reduced by about 18%, which means around four fewer serious events per 100 people over three years.
However, the benefits quickly decreased when people stopped taking the drugs. Even a break of six months was linked to a noticeable increase in risk compared to continuous use. People who interrupted treatment and later restarted it still did not regain the full protective benefit.
The longer the gap in treatment, the greater the risk. Those who stopped the medication for one year had a much higher risk, and those who stopped for two years saw up to a 22% increase in the risk of serious heart problems compared to people who continued taking the medication.
The researchers also found that about one-quarter of people stopped taking GLP-1 drugs during the study, and nearly another quarter had long interruptions. This shows that stopping treatment is common in real life. Many people stop because of side effects, high costs, or difficulty getting the medication.
The study suggests that when people stop these drugs, their bodies quickly lose the benefits they had gained. Blood pressure, cholesterol, and inflammation may rise again, even if the changes are not immediately obvious. This sudden reversal has been described by the researchers as a kind of “metabolic whiplash,” which may harm the heart.
Interestingly, restarting the medication after stopping did help reduce risk again, but the protection was not as strong as before. This suggests that stopping treatment may have lasting effects that are not fully reversible.
The study also found that the benefits of GLP-1 drugs build up slowly over time. People who took the drugs for longer periods gained more protection. In contrast, those who used them for less than 18 months and then stopped did not show significant long-term benefits compared to people using other diabetes medications.
These findings highlight an important message. GLP-1 drugs appear to work best when they are used continuously over a long period. Stopping and restarting treatment may reduce their effectiveness and increase health risks.
From a broader perspective, this study shows that GLP-1 medications are not just short-term treatments for weight loss. They are long-term therapies for chronic conditions. This means that patients and doctors need to think carefully about how to maintain treatment over time.
There are also important challenges to consider. The high cost of these drugs can make it difficult for some people to continue treatment. Side effects and supply shortages can also lead to interruptions.
The researchers suggest that healthcare systems should develop better ways to support patients, including managing side effects, reducing costs, and helping people stay on treatment.
From a critical point of view, this study is very strong because of its large size and long follow-up period. However, it focuses mainly on U.S. veterans, who may differ from the general population. In addition, as an observational study, it cannot prove cause and effect. Still, the results are consistent and highlight a clear pattern that deserves attention.
In conclusion, GLP-1 medications offer strong benefits for heart health, but these benefits depend on continuous use. Stopping the drugs, even for a short time, may increase the risk of serious heart problems. These findings suggest that long-term treatment and good support systems are essential for getting the full benefit of these medications.
If you care about weight loss, please read studies that hop extract could reduce belly fat in overweight people, and early time-restricted eating could help lose weight .
For more health information, please see recent studies about a simple path to weight loss, and results showing a non-invasive treatment for obesity and diabetes.
Copyright © 2026 Knowridge Science Report. All rights reserved.
